Sanofi's Libtayo Lands In EU With Skin Cancer Nod
Nine months after the US approval, the EU has followed suit and given a conditional approval for Sanofi and Regeneron’s IO Libtayo for a, so far, untreatable skin cancer.
Nine months after the US approval, the EU has followed suit and given a conditional approval for Sanofi and Regeneron’s IO Libtayo for a, so far, untreatable skin cancer.